Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
肾细胞癌有效抗肿瘤免疫的肿瘤和免疫决定因素
基本信息
- 批准号:10638907
- 负责人:
- 金额:$ 65.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-14 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:9p21.3AddressAdvanced Malignant NeoplasmApoptosisCD8-Positive T-LymphocytesCell CommunicationCell physiologyCellsCessation of lifeChromosome DeletionClear cell renal cell carcinomaClinicalCollaborationsCryopreservationDataDetectionDiseaseFlow CytometryFrequenciesGene MutationGeneticGenetic TranscriptionGenomicsImmuneImmune checkpoint inhibitorImmune responseImmunofluorescence ImmunologicImmunogenomicsImmunotherapeutic agentIn SituKnowledgeMacrophageMediatingMediatorMedicineMethodsModelingMutationNatureNeoplasm MetastasisPD-1 pathwayPatientsPhenotypePopulationPrimary NeoplasmProductionPrognosisProliferatingPublic HealthRecurrenceRenal Cell CarcinomaRenal carcinomaResistanceRoleSolid NeoplasmSpecimenStatistical ModelsStromal CellsT cell infiltrationT-LymphocyteTherapeutically TargetableTumor BurdenTumor ImmunityUnited StatesValidationWorkadvanced diseasecancer cellcancer infiltrating T cellsclinical translationcohortcytokineexhaustexome sequencinggenomic datahigh dimensionalityimmune cell infiltrateimmunogenicimmunoregulationimmunosuppressive macrophagesindustry partnerneoantigensnew therapeutic targetpharmacologicresponsesingle-cell RNA sequencingtherapy resistanttranscriptome sequencingtranscriptomicstreatment responsetumortumor microenvironmenttumor-immune system interactions
项目摘要
PROJECT SUMMARY
Immune checkpoint inhibitors (ICIs) targeting the PD-1 pathway have transformed the management of many
advanced cancers, including renal cell carcinoma (RCC), but most patients do not receive durable benefit from
these treatments. Whereas many efforts to understand ICI response and resistance in other tumor types have
often focused on investigating the role of total mutation burden (and consequent neoantigen load) or total T cell
infiltration in the tumor microenvironment (i.e. “hot” vs. “cold” tumors), RCC is biologically distinct from other
immunogenic solid tumors. In contrast to other solid tumors, the total mutation burden does not correlate with
response to ICI in RCC. Further, despite its relatively modest tumor mutational load, RCC stands out as one of
the most highly CD8+ T cell-infiltrated solid tumors at baseline, but the degree of CD8+ T cell infiltration into the
tumor-immune microenvironment (TME) does not associate with ICI response. These observations highlight the
gaps in our knowledge of the somatic alterations and infiltrating immune cell composition, phenotypic states, and
cellular interactions that mediate an effective immune response against RCC in the context of ICI. Thus, there is
a critical need to better understand the disease-specific mechanisms of response and resistance to current ICI-
based therapies in RCC, which may also uncover the general principles of how a modest mutation burden tumor
like RCC can be immunogenic. Prior smaller-scale analyses in RCC identified tumor-intrinsic somatic alterations
that impact ICI response in RCC, and co-occurring and interacting immune populations (terminally exhausted
CD8+ T cells and immunosuppressive macrophages) that are enriched in advanced disease. We therefore
hypothesize that somatic alterations and the TME interact to explain the unique immune landscape of RCC and
modulate response to ICI. By leveraging our expertise in immunogenomic analysis and our close collaborations
with academic and industry partners, we are now uniquely poised to address this hypothesis. In Aim 1, we seek
to systematically define the recurrent somatic alterations that impact immune infiltration and therapeutic
response through the interrogation of large-scale genomic data (whole exome sequencing and bulk RNA-
sequencing) from over 2,800 RCC tumors (including over 1,500 RCC tumors treated with ICI). In Aim 2, we strive
to uncover the cell composition and cellular interactions within the TME that mediate response to ICI through
large-scale single-cell transcriptomic analysis of 96 pre-treatment RCC tumor specimens (including 75 tumors
subsequently treated with ICI). We aim to validate inferred interactions using advanced spatial phenotyping
methods and through functional interrogation using an ex vivo patient-derived tumor fragment model. Overall,
this work will identify genetic and immune determinants of effective ICI-mediated anti-tumor immunity in RCC,
and will nominate specific therapeutically targetable immune inhibitory interactions in the TME for clinical
translation for patients with RCC (and potentially other low and intermediate mutation burden tumors).
项目摘要
针对PD-1途径的免疫检查点抑制剂(ICI)已改变了许多
高级癌症,包括肾细胞癌(RCC),但大多数患者没有从
这些治疗方法。尽管了解其他肿瘤类型的ICI反应和抵抗的许多努力具有
通常专注于研究总突变伯嫩(以及随之而来的新抗原负载)或总T细胞的作用
肿瘤微环境中的浸润(即“热”与“冷”肿瘤),RCC在生物学上与其他不同
免疫原性实体瘤。与其他实体瘤相反,总突变燃烧与
RCC中对ICI的响应。此外,其相对适度的肿瘤突变负荷,RCC脱颖而出
基线时最高的CD8+ T细胞浸润的实体瘤,但CD8+ T细胞的程度浸润
肿瘤免疫微环境(TME)不与ICI响应相关。这些观察突出了
我们了解躯体改变和浸润免疫细胞组成,表型状态和
在ICI的背景下介导有效的RCC免疫反应的细胞相互作用。那是
迫切需要更好地了解疾病特异性的反应机制和对当前ICI的抵抗力
RCC中的基于疗法,这也可能揭示了适度突变如何燃烧肿瘤的一般原理
像RCC一样可以是免疫原性的。 RCC中先前的较小尺度分析确定了肿瘤内部体细胞改变
这会影响RCC中的ICI响应,以及同时发生和相互作用的免疫吞吐量(终止疲惫)
富含晚期疾病的CD8+ T细胞和免疫抑制巨噬细胞。因此,我们
假设躯体改变和TME相互作用,以解释RCC和
调节对ICI的响应。通过利用我们在免疫基因组分析方面的专业知识和我们的亲密合作
与学术和行业合作伙伴有关,我们现在被中毒以解决这一假设。在AIM 1中,我们寻求
系统地定义影响免疫浸润和治疗的复发躯体改变
通过询问大尺度基因组数据(整个外显子组测序和大量RNA-)的响应
测序)来自2,800多个RCC肿瘤(包括用ICI处理的1,500多个RCC肿瘤)。在AIM 2中,我们努力
发现TME内的细胞组成和细胞相互作用,通过
96个预处理RCC肿瘤标本的大规模单细胞转录组分析(包括75个肿瘤
我们旨在使用高级空间定型来验证推断的相互作用
方法和通过实体患者衍生的肿瘤片段模型的功能询问。全面的,
这项工作将确定有效的ICI介导的RCC中有效ICI介导的抗肿瘤免疫史的遗传和免疫确定因素,
并将提名TME中特定的具有治疗靶向的免疫抑制性相互作用以进行临床
RCC患者(以及其他低和中间突变伯嫩肿瘤)的翻译。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Braun其他文献
David Braun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Experiences of Discrimination, Dysbiosis, and Racial Disparities in Ovarian Cancer
卵巢癌中的歧视、生态失调和种族差异的经历
- 批准号:
10371537 - 财政年份:2023
- 资助金额:
$ 65.68万 - 项目类别:
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer
RNA m6A修饰在前列腺癌发病及耐药中的作用及机制
- 批准号:
10638634 - 财政年份:2023
- 资助金额:
$ 65.68万 - 项目类别:
Strategies to predict and overcome resistance to cancer immunotherapy
预测和克服癌症免疫治疗耐药性的策略
- 批准号:
10638167 - 财政年份:2023
- 资助金额:
$ 65.68万 - 项目类别:
Project: Survivorship Care Physical Activity Initiative to Improve Disparities in HRQoL for Prostate Cancer Survivors (RELate Study)
项目:旨在改善前列腺癌幸存者 HRQoL 差异的生存护理体力活动计划(RELate 研究)
- 批准号:
10911646 - 财政年份:2023
- 资助金额:
$ 65.68万 - 项目类别: